AI-generated · cited to primary sources · not investment advice
Tempus AI, Inc. - Class A Common Stock (TEM) Sep 2025 Filing Analysis
Does management do what it says?
The company significantly exceeded the minimum liquidity requirement of $25 million, reporting $660.5 million in cash, cash equivalents, and restricted cash as of September 30, 2025. (1 met across 1 tracked commitment)
“The Company is required to maintain a minimum liquidity of at least $25 million... The Company was in compliance with all covenants in the Credit Agreement as of September 30, 2025.”
R&D expenses increased from $119.7 million to $122.5 million for the nine months ended September 30, 2025, compared to the prior year period, confirming the absolute dollar growth trend. (1 met across 1 tracked commitment)
“These expenses, though expected to increase in absolute dollars, are expected to decrease modestly as a percentage of revenue in the long term, though they may fluctuate as a percentage from period to period due to the timing and extent of these expenses.”
The commitment remains active through December 31, 2026. The company continues to provide services under this agreement, though specific cumulative spend to date against the $220 million floor is not explicitly totaled in this quarter's report. (1 in progress across 1 tracked commitment)
“AstraZeneca has committed to spend a minimum of $220 million on such products and services during the term of the MSA. The term of the MSA will continue through December 31, 2026.”
Management has lowered the percentage of RPO expected to be recognized over the next 12 months from 59% (as of March 2025) to 49% as of September 30, 2025, suggesting a lengthening of contract fulfillment timelines. (1 revised across 1 tracked commitment)
“The Company’s remaining performance obligations related to multi-year contracts was $360.2 million as of September 30, 2025, of which the Company expects to recognize approximately 49% as revenue over the next year.”
See the full cited Management analysis of Tempus AI, Inc. - Class A Common Stock
How durable is the business?
The company's proprietary position was bolstered by the acquisition of Paige.AI, an AI company specializing in digital pathology, and the launch of a $200 million Foundation Model development project with Pathos. (1 expanding, 1 shifted)
“Paige is an AI company specializing in digital pathology. The Paige Acquisition is expected to allow the Company to grow its dataset and establish a strong footprint in digital pathology with an industry leading technology portfolio.”
See the full cited Business Model analysis of Tempus AI, Inc. - Class A Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.